9 research outputs found
Clinical spectrum time course in non-Asian patients positive for anti-MDA5 antibodies
Objectives: To define the clinical spectrum time-course and prognosis of non-Asian patients positive for anti-MDA5 antibodies.
Methods: We conducted a multicentre, international, retrospective cohort study.
Results: 149 anti-MDA5 positive patients (median onset age 53 years, median disease duration 18 months), mainly females (100, 67%), were included. Dermatomyositis (64, 43%) and amyopathic dermatomyositis (47, 31%), were the main diagnosis; 15 patients (10%) were classified as interstitial pneumonia with autoimmune features (IPAF) and 7 (5%) as rheumatoid arthritis. The main clinical findings observed were myositis (84, 56%), interstitial lung disease (ILD) (108, 78%), skin lesions (111, 74%), and arthritis (76, 51%). The onset of these manifestations was not concomitant in 74 cases (50%). Of note, 32 (21.5%) patients were admitted to the intensive care unit for rapidly progressive-ILD, which occurred in median 2 months from lung involvement detection, in the majority of cases (28, 19%) despite previous immunosuppressive treatment. One-third of patients (47, 32% each) was ANA and anti-ENA antibodies negative and a similar percentage was anti-Ro52 kDa antibodies positive. Non-specific interstitial pneumonia (65, 60%), organising pneumonia (23, 21%), and usual interstitial pneumonia-like pattern (14, 13%) were the main ILD patterns observed. Twenty-six patients died (17%), 19 (13%) had a rapidly progressive-ILD.
Conclusions: The clinical spectrum of the anti-MDA5 antibodies-related disease is heterogeneous. Rapidly-progressive ILD deeply impacts the prognosis also in non-Asian patients, occurring early during the disease course. Anti-MDA5 antibody positivity should be considered even when baseline autoimmune screening is negative, anti-Ro52 kDa antibodies are positive, and radiology findings show a NSIP pattern
Recommended from our members
Identifying the Best Machine Learning Algorithms for Brain Tumor Segmentation, Progression Assessment, and Overall Survival Prediction in the BRATS Challenge
Gliomas are the most common primary brain malignancies, with different
degrees of aggressiveness, variable prognosis and various heterogeneous
histologic sub-regions, i.e., peritumoral edematous/invaded tissue, necrotic
core, active and non-enhancing core. This intrinsic heterogeneity is also
portrayed in their radio-phenotype, as their sub-regions are depicted by
varying intensity profiles disseminated across multi-parametric magnetic
resonance imaging (mpMRI) scans, reflecting varying biological properties.
Their heterogeneous shape, extent, and location are some of the factors that
make these tumors difficult to resect, and in some cases inoperable. The amount
of resected tumor is a factor also considered in longitudinal scans, when
evaluating the apparent tumor for potential diagnosis of progression.
Furthermore, there is mounting evidence that accurate segmentation of the
various tumor sub-regions can offer the basis for quantitative image analysis
towards prediction of patient overall survival. This study assesses the
state-of-the-art machine learning (ML) methods used for brain tumor image
analysis in mpMRI scans, during the last seven instances of the International
Brain Tumor Segmentation (BraTS) challenge, i.e., 2012-2018. Specifically, we
focus on i) evaluating segmentations of the various glioma sub-regions in
pre-operative mpMRI scans, ii) assessing potential tumor progression by virtue
of longitudinal growth of tumor sub-regions, beyond use of the RECIST/RANO
criteria, and iii) predicting the overall survival from pre-operative mpMRI
scans of patients that underwent gross total resection. Finally, we investigate
the challenge of identifying the best ML algorithms for each of these tasks,
considering that apart from being diverse on each instance of the challenge,
the multi-institutional mpMRI BraTS dataset has also been a continuously
evolving/growing dataset
Identifying the Best Machine Learning Algorithms for Brain Tumor Segmentation, Progression Assessment, and Overall Survival Prediction in the BRATS Challenge
Gliomas are the most common primary brain malignancies, with different
degrees of aggressiveness, variable prognosis and various heterogeneous
histologic sub-regions, i.e., peritumoral edematous/invaded tissue, necrotic
core, active and non-enhancing core. This intrinsic heterogeneity is also
portrayed in their radio-phenotype, as their sub-regions are depicted by
varying intensity profiles disseminated across multi-parametric magnetic
resonance imaging (mpMRI) scans, reflecting varying biological properties.
Their heterogeneous shape, extent, and location are some of the factors that
make these tumors difficult to resect, and in some cases inoperable. The amount
of resected tumor is a factor also considered in longitudinal scans, when
evaluating the apparent tumor for potential diagnosis of progression.
Furthermore, there is mounting evidence that accurate segmentation of the
various tumor sub-regions can offer the basis for quantitative image analysis
towards prediction of patient overall survival. This study assesses the
state-of-the-art machine learning (ML) methods used for brain tumor image
analysis in mpMRI scans, during the last seven instances of the International
Brain Tumor Segmentation (BraTS) challenge, i.e., 2012-2018. Specifically, we
focus on i) evaluating segmentations of the various glioma sub-regions in
pre-operative mpMRI scans, ii) assessing potential tumor progression by virtue
of longitudinal growth of tumor sub-regions, beyond use of the RECIST/RANO
criteria, and iii) predicting the overall survival from pre-operative mpMRI
scans of patients that underwent gross total resection. Finally, we investigate
the challenge of identifying the best ML algorithms for each of these tasks,
considering that apart from being diverse on each instance of the challenge,
the multi-institutional mpMRI BraTS dataset has also been a continuously
evolving/growing dataset
Cardiovascular Efficacy and Safety of Bococizumab in High-Risk Patients
Bococizumab is a humanized monoclonal antibody that inhibits proprotein convertase subtilisin- kexin type 9 (PCSK9) and reduces levels of low-density lipoprotein (LDL) cholesterol. We sought to evaluate the efficacy of bococizumab in patients at high cardiovascular risk. METHODS In two parallel, multinational trials with different entry criteria for LDL cholesterol levels, we randomly assigned the 27,438 patients in the combined trials to receive bococizumab (at a dose of 150 mg) subcutaneously every 2 weeks or placebo. The primary end point was nonfatal myocardial infarction, nonfatal stroke, hospitalization for unstable angina requiring urgent revascularization, or cardiovascular death; 93% of the patients were receiving statin therapy at baseline. The trials were stopped early after the sponsor elected to discontinue the development of bococizumab owing in part to the development of high rates of antidrug antibodies, as seen in data from other studies in the program. The median follow-up was 10 months. RESULTS At 14 weeks, patients in the combined trials had a mean change from baseline in LDL cholesterol levels of -56.0% in the bococizumab group and +2.9% in the placebo group, for a between-group difference of -59.0 percentage points (P<0.001) and a median reduction from baseline of 64.2% (P<0.001). In the lower-risk, shorter-duration trial (in which the patients had a baseline LDL cholesterol level of ≥70 mg per deciliter [1.8 mmol per liter] and the median follow-up was 7 months), major cardiovascular events occurred in 173 patients each in the bococizumab group and the placebo group (hazard ratio, 0.99; 95% confidence interval [CI], 0.80 to 1.22; P = 0.94). In the higher-risk, longer-duration trial (in which the patients had a baseline LDL cholesterol level of ≥100 mg per deciliter [2.6 mmol per liter] and the median follow-up was 12 months), major cardiovascular events occurred in 179 and 224 patients, respectively (hazard ratio, 0.79; 95% CI, 0.65 to 0.97; P = 0.02). The hazard ratio for the primary end point in the combined trials was 0.88 (95% CI, 0.76 to 1.02; P = 0.08). Injection-site reactions were more common in the bococizumab group than in the placebo group (10.4% vs. 1.3%, P<0.001). CONCLUSIONS In two randomized trials comparing the PCSK9 inhibitor bococizumab with placebo, bococizumab had no benefit with respect to major adverse cardiovascular events in the trial involving lower-risk patients but did have a significant benefit in the trial involving higher-risk patients